Boston Scientific Corp (XTER:BSX)
€ 86.5 -0.5 (-0.57%) Market Cap: 126.52 Bil Enterprise Value: 134.81 Bil PE Ratio: 74.93 PB Ratio: 6.45 GF Score: 79/100

Boston Scientific Corp at Truist Securities Life Sciences Summit Transcript

May 05, 2021 / 02:30PM GMT
Release Date Price: €36.04 (+0.11%)
Kaila Paige Krum
Truist Securities, Inc., Research Division - Research Analyst

Great. Hi, everyone. I cover the Medtech space here at True Securities with my team, David Rescott and Sam Brodovsky. We appreciate you joining us this call today. Before we begin, I need to read the following disclaimer. This call is arranged by Truist Securities research for use by institutional investors and issuer clients as defined by FINRA. If you're not an institutional investor or issuer, please disconnect at this time, For required disclosures, please see our website at truistsecurities.com or our equity research library.

On today's call, we have the Investor Relations team from Boston Scientific, including Vice President Susie Lisa and Director Lauren Tengler. I'll start out the call, but if anyone on the line has any questions for management, please e-mail them to me at Kaila, K-A-I-L-A, dot Krum, K-R-U-M, at Truist, T-R-U-I-S-T, dot com, and I'll do my best to get those in.

So Susie, Lauren, thanks so much for joining us today, and sorry about the long-winded intro, but it's great to see you both

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot